CureVac N.V. (CVAC)

41.81 -0.24 (-0.56%) As of 09:49AM EST. Market open.

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 455

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Franz-Werner Haas L.L.M., LLD, Ph.D., LL.M.	CEO & Member of Management Board	680.91k	N/A	1970
Mr. Pierre Kemula B.Sc.	MD, CFO & Member of Management Board	662.38k	N/A	1974
Ms. Mariola Fotin-Mleczek	CTO & Member of Management Board	529.71k	N/A	1968
Dr. Igor Splawski M.Sc., Ph.D.	Chief Scientific Officer & Member of Management Board	446.47k	N/A	1969
Dr. Antony Blanc	MD, Chief Bus. Officer & Chief Commercial Officer	403.8k	N/A	1969
Dr. Klaus Edvardsen M.D., Ph.D.	Chief Devel. Officer	N/A	N/A	N/A
Mr. Malte Greune Ph.D.	COO & Member of Management Board	N/A	N/A	N/A
Dr. Sarah Fakih	VP Corp. Communications & Investor Relations	N/A	N/A	N/A
Mr. Thorsten Schuller	Head of Corp. Communications	N/A	N/A	N/A
Slavica Stevanovic-Heck	Head of HR	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Corporate governance

CureVac N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.